Levi & Korsinsky, LLP | Securities Class Action Attorneys

Upcoming Deadlines

Investors interested in taking an active role in litigation have a limited time to petition the court for appointment as lead plaintiff. If you are interested in acting as a lead plaintiff, submit your transactions before the deadline, and our analysts will calculate your losses. Don't wait till the last minute- discuss your options today.
View All Deadlines

Days Left

AAPL

Apple Inc.

Deadline

August 19 2025

Class Period

6/10/24 - 6/9/25

Allegations

(i) Apple misstated the time it would take to integrate the advanced AI-based Siri features into its devices; (ii) accordingly, it was highly unlikely that these features would be available for the iPhone 16; (iii) the lack of such advanced AI-based features would hurt iPhone 16 sales; (iv) as a result, Apple’s business and/or financial prospects were overstated; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

6/10/24 - 6/9/25

Deadline

August 19 2025

Learn More

Days Left

SRPT

Sarepta Therapeutics, Inc.

Deadline

August 25 2025

Class Period

6/22/23 - 6/24/25

Allegations

(i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii) the severity of adverse events from ELEVIDYS treatment would cause the Company to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy’s present and expanded approvals; and (iv) as a result of the foregoing, defendants materially misled with, and/or lacked a reasonable basis for, their positive statements.

Class Period

6/22/23 - 6/24/25

Deadline

August 25 2025

Learn More

Days Left

HIMS

Hims & Hers Health, Inc.

Deadline

August 25 2025

Class Period

4/29/25 - 6/23/25

Allegations

(1) Hims was engaged in the “deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk;” (2) as a result, there was a substantial risk that the Company’s collaboration with Novo Nordisk would be terminated; and (3) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

4/29/25 - 6/23/25

Deadline

August 25 2025

Learn More

Days Left

WOOF

Petco Health and Wellness Company, Inc.

Deadline

August 29 2025

Class Period

1/14/21 - 6/5/25

Allegations

(i) Petco’s pandemic-related tailwinds were unsustainable, as was its business model of selling primarily premium and/or high-grade pet food; (ii) accordingly, the strength of Petco’s differentiated product strategy was overstated; (iii) defendants downplayed the true scope and severity of the foregoing issues, the magnitude of changes needed to rectify those issues, and the likely negative impacts of their mitigation strategy on Petco’s comparable sales metric; (iv) accordingly, defendants overstated Petco’s ability to deliver sustainable, profitable growth; and (v) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

1/14/21 - 6/5/25

Deadline

August 29 2025

Learn More

Days Left

IRBT

iRobot Corporation

Deadline

September 5 2025

Class Period

1/29/24 - 3/11/25

Allegations

(i) iRobot overstated the extent to which the restructuring plan would help the Company maintain stability after the termination of the Amazon acquisition; (ii) as a result, it was unlikely that iRobot would be able to profitably operate as a standalone company; (iii) accordingly, there was substantial doubt about the Company’s ability to continue as a going concern; and (iv) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

1/29/24 - 3/11/25

Deadline

September 5 2025

Learn More

Days Left

CNC

Centene Corporation

Deadline

September 8 2025

Class Period

12/12/24 - 6/30/25

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Centene’s enrollment and morbidity rates. Investors began to question the veracity of defendants’ public statements on July 1, 2025, when Centene issued a press release withdrawing 2025 guidance. Particularly, following an analysis of the 2025 Health Insurance Marketplace, Centene’s overall market growth across 22 states, or 72% of the Company’s marketplace membership, was lower than expected. In pertinent part, the Company stated that this preliminary analysis resulted in a reduction of its previously issued guidance to approximately $1.8 billion or an adjusted diluted EPS of $2.75. Following this news, Centene’s common stock declined dramatically, from a closing market price of $56.65 per share on July 1, 2025, Centene’s stock price fell to $33.78 per share on July 2, 2025, a decline of 40.4%.

Class Period

12/12/24 - 6/30/25

Deadline

September 8 2025

Learn More

Days Left

XIFR

XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP

Deadline

September 8 2025

Class Period

9/27/23 - 1/27/25

Allegations

(i) XPLR was struggling to maintain its operations as a yieldco; (ii) defendants temporarily relieved this issue by entering into certain financing arrangements, described herein, while downplaying the attendant risks; (iii) XPLR could not resolve those financings before their maturity date without risking significant unitholder dilution; (iv) as a result, defendants planned to halt cash distributions to investors and instead redirect those funds to, inter alia, resolve those financings; (v) as a result of all the foregoing, XPLR’s yieldco business model and distribution growth rate was unsustainable; and (vi) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

9/27/23 - 1/27/25

Deadline

September 8 2025

Learn More

Days Left

BHVN

Biohaven Ltd.

Deadline

September 12 2025

Class Period

3/24/23 - 5/14/25

Allegations

(i) The company's product candidate, troriluzole’s regulatory prospects as a treatment for SCA, and/or the sufficiency of data that Biohaven submitted in support of troriluzole’s regulatory approval for this indication, were overstated; (ii) BHV-7000’s efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely to have a significant negative impact on Biohaven’s business and financial condition; and (iv) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

3/24/23 - 5/14/25

Deadline

September 12 2025

Learn More

Days Left

CAPR

Capricor Therapeutics, Inc.

Deadline

September 15 2025

Class Period

10/9/24 - 7/10/25

Allegations

According to the complaint, defendants provided investors with material information concerning Capricor’s lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Defendants’ statements included, among other things, Capricor’s ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration (FDA). Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel. On July 11, 2025, Capricor issued a press release announcing it received a Complete Response Letter (CRL) from the FDA denying the BLA specifically citing it did not meet the statutory requirement for substantial evidence of effectiveness and the need for additional clinical data. Further, the CRL referenced outstanding items in the Chemistry, Manufacturing, and Controls section of the application. Following this news, the price of Capricor stock declined from $11.40 per share on July 10, 2025 to $7.64 per share on July 11, 2025.

Class Period

10/9/24 - 7/10/25

Deadline

September 15 2025

Learn More

Days Left

NEOG

Neogen Corporation

Deadline

September 16 2025

Class Period

1/5/23 - 6/3/25

Allegations

According to the filed complaint, defendants issued a series of materially false and misleading statements which led investors to believe that the integration with the Food Safety Division of the 3M Company was progressing much better than it actually was. In addition, even when the Company was forced to reveal that certain “inefficiencies” arose as a result of the integration, defendants downplayed them and assured investors that they were fully aware and committed to resolving them quickly.

Class Period

1/5/23 - 6/3/25

Deadline

September 16 2025

Learn More

Days Left

ANRO

Alto Neuroscience, Inc.

Deadline

September 19 2025

Class Period

This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about February 2, 2024; and/or (b) Alto securities between February 2, 2024 and October 22, 2024, both dates inclusive.

Allegations

(i) The Company’s product pipeline, ALTO-100, was less effective in treating major depressive disorder than defendants had led investors to believe; (ii) accordingly, ALTO-100’s clinical, regulatory, and commercial prospects were overstated; (iii) as a result, Alto’s business and/or financial prospects were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

Deadline

September 19 2025

Learn More

Days Left

REPL

Replimune Group, Inc.

Deadline

September 22 2025

Class Period

11/22/24 - 7/21/25

Allegations

(1) defendants recklessly overstated the IGNYTE trial’s prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants’ statements about Replimune’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

11/22/24 - 7/21/25

Deadline

September 22 2025

Learn More

Days Left

FI

Fiserv, Inc.

Deadline

September 22 2025

Class Period

7/24/24 - 7/22/25

Allegations

(a) Due to cost issues and other problems with its older point-of-sale platform, Payeezy, Fiserv forced Payeezy merchants to convert to its Clover platform; (b) Clover’s revenue growth and GPV growth were temporarily boosted by these conversions, which concealed a slowdown in new merchant business; (c) shortly after these conversions, a significant portion of former Payeezy merchants switched to competing solutions due to Clover’s high pricing, inadequate customer service, and other issues; (d) as a result of these merchant losses, Clover’s GPV growth was significantly slowing, and its revenue growth was unsustainable; and (e) based on the foregoing, Fiserv’s positive class period statements about Clover growth strategies, competition, attrition, GPV growth, and business prospects were materially false and misleading.

Class Period

7/24/24 - 7/22/25

Deadline

September 22 2025

Learn More

Days Left

RXST

RxSight, Inc.

Deadline

September 22 2025

Class Period

11/7/24 - 7/8/25

Allegations

(1) the Company was experiencing “adoption challenges” and/or structural issues resulting in declines in sales and utilization; (2) defendants had overstated the demand for RxSight’s products; (3) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025; and (4) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/7/24 - 7/8/25

Deadline

September 22 2025

Learn More

Days Left

FLYW

Flywire Corporation

Deadline

September 23 2025

Class Period

2/28/24 - 2/25/25

Allegations

(i) the strength and sustainability of Flywire’s revenue growth was overstated; (ii) the negative impact that permit- and visa-related restrictions were having and were likely to have on Flywire’s business was understated; and (iii) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

2/28/24 - 2/25/25

Deadline

September 23 2025

Learn More

Days Left

SOC

Sable Offshore Corp.

Deadline

September 26 2025

Class Period

This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded Sable Offshore securities between May 19, 2025 and June 3, 2025, inclusive, and/or pursuant and/or traceable to the Company’s May 21, 2025 secondary public offering.

Allegations

(1) defendants represented that Sable Offshore Corp. had restarted oil production off the coast of California when it had not; and (2) as a result, defendants statements about Sables business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Class Period

Deadline

September 26 2025

Learn More

Days Left

LMT

Lockheed Martin Corporation

Deadline

September 26 2025

Class Period

1/23/24 - 7/21/25

Allegations

(1) Lockheed Martin lacked effective internal controls regarding its purportedly risk adjusted contracts including the reporting of its risk adjusted profit booking rate; (2) Lockheed Martin lacked effective procedures to perform reasonably accurate comprehensive reviews of program requirements, technical complexities, schedule, and risks; (3) Lockheed Martin overstated its ability to deliver on its contract commitments in terms of cost, quality and schedule; (4) as a result, the Company was reasonably likely to report significant losses; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

1/23/24 - 7/21/25

Deadline

September 26 2025

Learn More

Days Left

NVO

Novo Nordisk A/S

Deadline

September 30 2025

Class Period

5/7/25 - 7/28/25

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Novo’s growth potential; notably, that its asserted potential to capitalize on the compounded market greatly understated the potential impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood such patients would switch to Novo’s branded alternatives, and further greatly overstated the potential GLP-1 market or otherwise Novo’s capability to penetrate said markets to achieve continued growth. On July 29, 2025, Novo announced it was lowering its sales and profit outlook ahead of reporting its results for the second quarter of fiscal year 2025. The Company attributed the guide down on “lowered growth expectations for the second half of 2025” for both Wegovy and Ozempic due to “the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition.” Following this news, the price of Novo’s common stock declined dramatically. From a closing market price of $69.00 per share on July 28, 2025, Novo’s stock price fell to $53.94 per share on July 29, 2025, a decline of about 21.83% in the span of just a single day.

Class Period

5/7/25 - 7/28/25

Deadline

September 30 2025

Learn More

Days Left

LINE

Lineage, Inc.

Deadline

September 30 2025

Class Period

This lawsuit is on behalf of all purchasers of Lineage common stock in or traceable to the registration statement used in connection with the Company’s July 26, 2024 initial public offering.

Allegations

(a) Lineage was then experiencing sustained weakening in customer demand, as additional cold-storage supply had come on line, the Company’s customers destocked a glut of excessive inventory built up during the COVID-19 pandemic, and the Company’s customers shifted to maintaining leaner cold-storage inventories on a go-forward basis in response to changed consumer trends; (b) Lineage had implemented price increases in the lead-up to the IPO that could not be sustained in light of the weakening demand environment facing the Company; (c) Lineage was unable to effectively counteract the adverse trends listed in (a)-(b) above through the use of minimum storage guarantees or as a result of operational efficiencies, technological improvements, or its purported competitive advantages; (d) that, as a result of (a)-(c) above, rather than enjoying stable revenue growth, high occupancy rates, and steady rent escalation as represented in the registration statement, Lineage was in fact suffering from stagnant or falling revenue, occupancy rates, and rent prices; and (e) that, as a result of (a)-(d) above, Lineage’s financial results, business operations, and prospects were materially impaired.

Class Period

This lawsuit is on behalf of all purchasers of Lineage common stock in or traceable to the registration statement used in connection with the Company’s July 26, 2024 initial public offering.

Deadline

September 30 2025

Learn More

Days Left

TSLA

Tesla, Inc.

Deadline

October 3 2025

Class Period

4/19/23 - 6/22/25

Allegations

(i) Tesla overstated the effectiveness of its autonomous driving technology; (ii) there was thus a significant risk that the Company’s autonomous driving vehicles, including the Robotaxi, would operate dangerously and/or in violation of traffic laws; (iii) the foregoing increased the likelihood that Tesla would become subject to heightened regulatory scrutiny; (iv) accordingly, Tesla’s business and/or financial prospects were overstated; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times

Class Period

4/19/23 - 6/22/25

Deadline

October 3 2025

Learn More

Days Left

ALT

Altimmune, Inc.

Deadline

October 6 2025

Class Period

8/10/23 - 6/25/25

Allegations

According to the complaint, on June 26, 2025, Altimmune published a press release announcing topline results from the IMPACT Phase 2b MASH trial of Pemvidutide in the Treatment of MASH. While defendants had continuously provided inflated expectations ahead of these results, the analysis showed a pointed failure by the Company to achieve statistical significance in its analysis of the fibrosis reduction primary endpoint in its IMPACT Phase 2b MASH trial. In particular, while a positive trend in fibrosis improvement was observed, statistical significance was not met due to a higher-than-expected placebo response. When questioned about this concerning miss, defendants answered indifferently, attributing this result to the Phase 2 nature of the trial and stated that Altimmune was hoping for better results following the Phase 3 trial. Following this news, the price of Altimmune’s common stock declined dramatically. From a closing market price of $7.71 per share on June 25, 2025, Altimmune’s stock price fell to $3.61 per share on June 26, 2025, a decline of 53.2% in the span of just a single day.

Class Period

8/10/23 - 6/25/25

Deadline

October 6 2025

Learn More

Days Left

CTO

CTO Realty Growth, Inc.

Deadline

October 7 2025

Class Period

2/18/21 - 6/24/25

Allegations

(i) CTO’s dividends were less sustainable than defendants had led investors to believe; (ii) the Company used deceptive and unsustainable practices to artificially inflate its adjusted funds from operations and overstate the true profitability of its Ashford Lane property; (iii) accordingly, CTO’s business and/or financial prospects were overstated; and (iv) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

2/18/21 - 6/24/25

Deadline

October 7 2025

Learn More

356251

Days Left

AOUT

American Outdoor Brands, Inc.

Deadline

January 1 3001

Class Period

7/2/20 - 7/2/25

Allegations

American Outdoor issued a press release on June 26, 2025, reporting its financial results for its fourth quarter and full fiscal year 2025. Among other items, American Outdoor disclosed that retailers accelerated orders in the final weeks of the quarter, effectively pulling forward an estimated $8 million to $10 million in sales from the upcoming fiscal year. American Outdoor also announced its decision to suspend its fiscal 2026 guidance, citing uncertainties around tariffs. Following this news, American Outdoor's stock price fell over 13% on June 27, 2025.

Class Period

7/2/20 - 7/2/25

Deadline

January 1 3001

Learn More

View All Deadlines

Never Miss a Potential Recovery Again

Sign up for Class Action Alerts

$549,350,000 in Total Settlement Funds Available. See if you qualify!Find Out More

We Give Shareholders A Voice.

Settlements

Who We Are

Find an Attorney

Find a Case

Upcoming Deadlines

AAPL

Apple Inc.

SRPT

Sarepta Therapeutics, Inc.

HIMS

Hims & Hers Health, Inc.

WOOF

Petco Health and Wellness Company, Inc.

IRBT

iRobot Corporation

CNC

Centene Corporation

XIFR

XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP

BHVN

Biohaven Ltd.

CAPR

Capricor Therapeutics, Inc.

NEOG

Neogen Corporation

ANRO

Alto Neuroscience, Inc.

REPL

Replimune Group, Inc.

FI

Fiserv, Inc.

RXST

RxSight, Inc.

FLYW

Flywire Corporation

SOC

Sable Offshore Corp.

LMT

Lockheed Martin Corporation

NVO

Novo Nordisk A/S

LINE

Lineage, Inc.

TSLA

Tesla, Inc.

ALT

Altimmune, Inc.

CTO

CTO Realty Growth, Inc.

AOUT

American Outdoor Brands, Inc.

News

PEPG Crashes as Duchenne Drug Fails, Investors Sue

Reckitt Sued as Enfamil Risks Emerge

Levi & Korsinsky Announces Pendency, Settlement Hearing, & More in The Necessity Retail Reit, Inc. Class Action

Our World-Class Team

Sign up for Class
Action Alerts